Cristina Chiriaco - Search Results

Year	Number of Results
2008	1
2010	1
2013	3
2014	1
2015	1
2016	1
2019	1
2020	1
2021	1
2022	3
2024	0

1

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy.

Chiriaco C, Donini C, Cortese M, Ughetto S, Modica C, Martinelli I, Proment A, Vitali L, Fontani L, Casucci M, Comoglio PM, Giordano S, Sangiolo D, Leuci V, Vigna E. Chiriaco C, et al. J Exp Clin Cancer Res. 2022 Oct 21;41(1):309. doi: 10.1186/s13046-022-02479-y. J Exp Clin Cancer Res. 2022. PMID: 36271379 Free PMC article.

2

Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of 'MET-addicted' cancers.

Martinelli I, Modica C, Chiriaco C, Basilico C, Hughes JM, Corso S, Giordano S, Comoglio PM, Vigna E. Martinelli I, et al. Among authors: chiriaco c. J Exp Clin Cancer Res. 2022 May 24;41(1):180. doi: 10.1186/s13046-022-02398-y. J Exp Clin Cancer Res. 2022. PMID: 35606837 Free PMC article. No abstract available.

3

hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of 'MET-addicted' cancers.

Martinelli I, Modica C, Chiriaco C, Basilico C, Hughes JM, Corso S, Giordano S, Comoglio PM, Vigna E. Martinelli I, et al. Among authors: chiriaco c. J Exp Clin Cancer Res. 2022 Mar 29;41(1):112. doi: 10.1186/s13046-022-02320-6. J Exp Clin Cancer Res. 2022. PMID: 35351166 Free PMC article.

4

A receptor-antibody hybrid hampering MET-driven metastatic spread.

Modica C, Basilico C, Chiriaco C, Borrelli N, Comoglio PM, Vigna E. Modica C, et al. Among authors: chiriaco c. J Exp Clin Cancer Res. 2021 Jan 14;40(1):32. doi: 10.1186/s13046-020-01822-5. J Exp Clin Cancer Res. 2021. PMID: 33446252 Free PMC article.

5

Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody.

Modica C, Gallo S, Chiriaco C, Spilinga M, Comoglio PM, Crepaldi T, Basilico C, Vigna E. Modica C, et al. Among authors: chiriaco c. Cancers (Basel). 2020 Mar 21;12(3):741. doi: 10.3390/cancers12030741. Cancers (Basel). 2020. PMID: 32245152 Free PMC article.

6

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.

Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, Perera T, Gammaitoni L, Aglietta M, Comoglio PM, Vigna E, Sangiolo D. Martin V, et al. Among authors: chiriaco c. Br J Cancer. 2019 Mar;120(5):527-536. doi: 10.1038/s41416-018-0315-3. Epub 2019 Feb 6. Br J Cancer. 2019. PMID: 30723303 Free PMC article.

7

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Cignetto S, Modica C, Chiriaco C, Fontani L, Milla P, Michieli P, Comoglio PM, Vigna E. Cignetto S, et al. Among authors: chiriaco c. Mol Oncol. 2016 Jun;10(6):938-48. doi: 10.1016/j.molonc.2016.03.004. Epub 2016 Mar 28. Mol Oncol. 2016. PMID: 27103110 Free PMC article.

8

Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.

Vigna E, Chiriaco C, Cignetto S, Fontani L, Basilico C, Petronzelli F, Comoglio PM. Vigna E, et al. Among authors: chiriaco c. Mol Oncol. 2015 Nov;9(9):1760-72. doi: 10.1016/j.molonc.2015.05.007. Epub 2015 Jun 5. Mol Oncol. 2015. PMID: 26119717 Free PMC article.

9

Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.

Vigna E, Pacchiana G, Chiriaco C, Cignetto S, Fontani L, Michieli P, Comoglio PM. Vigna E, et al. Among authors: chiriaco c. J Mol Med (Berl). 2014 Jan;92(1):65-76. doi: 10.1007/s00109-013-1079-0. Epub 2013 Sep 7. J Mol Med (Berl). 2014. PMID: 24013625 Free article.

10

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.

Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L. Olwill SA, et al. Among authors: chiriaco c. Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3. Mol Cancer Ther. 2013. PMID: 24002935

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

13 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year